Business Wire

BRAUN

Share
Braun Launches the World’s First Smart At-Home IPL System That Learns and Adapts to Your Skin and Hair to Give You 1 Year of Smooth Skin*

From its home of IPL at its world-class innovation facility in Kronberg, Germany, the pioneering German electronics brand, Braun, today introduces the Braun Skin i·expert - the only fully connected IPL system that learns, adapts, and provides personalised feedback in real time.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240131964639/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Braun Skin i·expert. Fully connected IPL system. (Photo: Business Wire)

The revolutionary new Skin i·expert is Braun’s fastest way to 1 year of smooth skin*, all in the comfort of your own home.

A smart system that automatically adapts the energy to your skin tone providing you with an active real-time personalised treatment guidance per body area – Braun puts the power in your hands, offering a more comfortable hair removal experience with the new Braun Skin i·expert.

All IPL devices within the Braun portfolio have been designed to offer fast, safe, almost painless hair removal and undergo countless R&D tests and scientific research to deliver the desired results you want and need.

Braun IPL devices are assessed by independent dermatologists and certified by Skin Health Alliance's high skin safety standards

  • Smart Coverage Feedback and Smart Head Recognition enables you to achieve your best results by guiding you in real-time to avoid missing any treatment areas.
  • The only one** with automatic flash power adaptation to your unique skin tones and a Skin Check to achieve your best results, in full safety. Followed by personalized tips on how you can improve your next session.
  • No need to worry about missing an appointment thanks to its built in Personal Progress Tracker and Smart Calendar that enables you to stay on track by automatically adapting the sessions schedule by showing you how many treatments you still have left. Take control of your hair removal journey with ease and at a fraction of the cost of going to a salon.

Braun’s new IPL smart device is a step change to your hair removal routine, it gives the power to you to get long-lasting smooth skin safely, easily from the comfort of your home.

Ahmed Aboulenein, Global Vice President at Braun, said: “At Braun's Kronberg Innovation Center, our team are committed to designing durable and user-centered innovations that leverage cutting-edge technologies. Our aim is to delight consumers and address their Grooming everyday problems effectively. By gathering insights and data from consumers worldwide, Braun has identified a need for solutions that enable users to achieve safe and long-lasting smooth skin at home. This valuable information has informed our latest breakthrough IPL innovation. Our ultimate objective is to empower consumers, allowing them to achieve safe, long-lasting smooth skin comfortably from the convenience of their own homes. What sets the new Braun Skin i-expert apart is its seamless integration of smart technology, connecting the IPL device with a dedicated mobile app. This comprehensive system learns and adapts to the user's specific skin and hair needs, guiding them step by step through the entire treatment process. It provides real-time personalized feedback, making it remarkably user-friendly for both experienced IPL users and beginners.”

Dr. Christine Dierickx, MD, a leading cosmetic dermatologist and Director of Skinperium Laser and Cosmetic Dermatology Clinic in Luxembourg, said: “Hair removal is one of the top three reasons why patients visit a dermatologist. Many consumers opt also for salons as they believe at-home devices are complicated and do not deliver the desired results. The Braun Skin i·expert is a unique device that has been developed after years of research. It features an intuitive smart system that makes hair removal extremely simple for consumers. The device learns use after use to provide a personalized experience tailored just to you. Additionally, the automatic flash power adapts to your unique skin tones to ensure you achieve the best results, in full safety. The new Braun Skin i·expert is set to revolutionize the way we remove hair at home.”

*Following the regimen. Individual results may vary.

**Shared technology with Cyden

***Further reading: Hattersley AM, Kiernan M, Goldberg D, Dierickx C, Sliney DH, Haedersdal M, et al. Assessment of adverse events for a home‐use intense pulsed light hair removal device using postmarketing surveillance. Lasers Surg Med. 2023;1–9. https://doi.org/10.1002/lsm.23650

Notes to editors

About Braun

Braun, a subsidiary of Procter & Gamble founded in Germany in 1921, develops and manufactures a wide variety of small domestic appliances that marry technical innovation, reliable quality and distinctive design. These range from electric shavers and beauty products to household appliances, watches and speakers. Braun products enjoy worldwide distribution. Please visit www.braun.com for the latest news and in-depth information about the Braun brand.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240131964639/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye